Non Transplantable Recurrence After Percutaneous Thermal Ablation of HCC

NCT05202184 | Completed

• 1 other identifier: RECHMPL17_0436_3
• Study Type: observational
• Target: 213
• Locations: 1 country
• Sites: 1

Brief Summary

Percutaneous thermal ablation (PTA), resection and liver transplantation (LT) are the standard curative options for hepatocellular carcinoma (HCC). LT yields the best long-term outcomes but is limited by graft shortage. Thus, patients with ≤3cm HCC are mainly treated by PTA although recurrence is frequent and may occur outside transplant criteria. However, data on non transplantable recurrence (NTR) following PTA are lacking. Therefore, the investigators investigated the incidence and predictors of NTR among transplantable patients with ≤3cm HCC(s) treated by PTA, in order to stratify them according to their NTR risk and to improve treatment allocation.

Conditions

HCC

Keywords

With or without cirrhosis; BCLC0 or A; No extra-hepatic disease; Radiofrequency ablation; Microwave ablation; Liver transplantation

Outcome Measures

Primary Outcomes (1)

• Incidence of non transplantable recurrence

  Incidence of non transplantable recurrence

  1 day

Study Arms (1)

Percutaneous thermal ablation of small HCC

Percutaneous thermal ablation of small HCC

Procedure: Percutaneous thermal ablation

Interventions

Percutaneous thermal ablation PROCEDURE

All thermoablation procedures were performed percutaneously under ultrasound and/or CT guidance

Percutaneous thermal ablation of small HCC

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Consecutive patients undergoing PTA for HCC between January 2015 and December 2020 were included. Data were collected from our prospective database at the Department of Radiology St-Eloi University Hospital - Montpellier School of Medicine France.

You may qualify if:

• HCC diagnosed by histopathology or by EASL imaging criteria
• HCC ≤30mm, 1 - 3 tumor nodules, follow-up\<3 months
• no prior or combined treatment with intra-arterial therapy
• potentially transplantable patient (ie, ≤70yr, AFP-score≤2 (7), no macroscopic portal vein invasion or extra-hepatic metastasis, no major comorbidity precluding LT).

You may not qualify if:

• \- age \< 18 years

Sponsors & Collaborators

• University Hospital, Montpellier: lead

Study Sites (1)

Uhmontpellier

Montpellier, 34295, France

Location

Study Officials

• BORIS GUIU, PU-PH

  University Hospital, Montpellier

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 7, 2022
• First Posted: January 21, 2022
• Study Start: January 1, 2015
• Primary Completion: December 1, 2020
• Study Completion: December 30, 2020
• Last Updated: February 8, 2022

Record last verified: 2022-01

Locations

FR (1)